Security
Sanofi Ordinary Shares (France) · SNYNF
SNYNFOTCCommon stockCurrentCIK 1121404Updated Oct 6, 2026
Name history
SANOFI-AVENTIS · through May 9, 2011SANOFI SYNTHELABO SA · through Aug 24, 2004
SNYNF price & chart
Loading TradingView…
OTC:SNYNF on TradingView ↗About the company
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · EURSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossEUR | 7,851,000,000Source | 5,618,000,000Source | 5,436,000,000Source | 8,484,000,000Source |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableEUR | -1,202,000,000Source | -28,000,000Source | -397,000,000Source | -777,000,000Source |
| AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociatesEUR | — | — | — | 0Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableEUR | 398,000,000Source | 789,000,000Source | 402,000,000Source | 452,000,000Source |
| AdjustmentsForSharebasedPaymentsEUR | 313,000,000Source | 278,000,000Source | 283,000,000Source | 245,000,000Source |
| DividendsPaidOrdinarySharesPerShareEUR/shares | 3.92Source | 3.76Source | 3.56Source | 3.33Source |
| GoodwillEUR | 41,300,000,000Source | 43,384,000,000Source | 49,404,000,000Source | 49,892,000,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesEUR | 2,885,000,000Source | 3,291,000,000Source | 2,623,000,000Source | 2,452,000,000Source |
| InterestPaidClassifiedAsOperatingActivitiesEUR | 485,000,000Source | 587,000,000Source | 559,000,000Source | 380,000,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesEUR | 331,000,000Source | 447,000,000Source | 547,000,000Source | 173,000,000Source |
| OtherAdjustmentsToReconcileProfitLossEUR | 273,000,000Source | 68,000,000Source | 283,000,000Source | 138,000,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | 333,000,000Source | 282,000,000Source | 265,000,000Source | 291,000,000Source |
| PaymentsToAcquireOrRedeemEntitysSharesEUR | 5,030,000,000Source | 302,000,000Source | 593,000,000Source | 497,000,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesEUR | 5,559,000,000Source | 0Source | 48,000,000Source | 1,549,000,000Source |
| ProceedsFromIssuingSharesEUR | 177,000,000Source | 187,000,000Source | 195,000,000Source | 188,000,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesEUR | 2,622,000,000Source | 672,000,000Source | 3,684,000,000Source | 2,718,000,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseEUR | 9,543,000,000Source | 9,183,000,000Source | 10,692,000,000Source | 10,492,000,000Source |
| Total Revenue | — | — | — | — |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.26Source | 0.26Source | 0.26Source | 0.26Source |
| AverageEffectiveTaxRatenumber | 0.17Source | 0.18Source | 0.22Source | 0.19Source |
| BasicEarningsLossPerShareEUR/shares | 6.4Source | 4.44Source | — | — |
| CurrentTaxExpenseIncomeEUR | 3,437,000,000Source | 2,152,000,000Source | 2,560,000,000Source | 2,774,000,000Source |
| DeferredTaxExpenseIncomeEUR | -2,394,000,000Source | -948,000,000Source | -958,000,000Source | -768,000,000Source |
| DilutedEarningsLossPerShareEUR/shares | 6.37Source | 4.43Source | — | — |
| EmployeeBenefitsExpenseEUR | 9,806,000,000Source | 10,191,000,000Source | 9,814,000,000Source | 9,991,000,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesEUR | — | — | — | 245,000,000Source |
| FinanceCostsEUR | 563,000,000Source | 1,073,000,000Source | 1,313,000,000Source | 440,000,000Source |
| FinanceIncomeEUR | 394,000,000Source | 519,000,000Source | 591,000,000Source | 206,000,000Source |
| GrossProfitEUR | 33,667,000,000Source | 31,081,000,000Source | 32,208,000,000Source | 31,694,000,000Source |
| ImpairmentLossRecognisedInProfitOrLossGoodwillEUR | 0Source | 0Source | 0Source | 0Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillEUR | 2,241,000,000Source | 248,000,000Source | 896,000,000Source | -454,000,000Source |
| IncomeTaxExpenseContinuingOperationsEUR | 1,043,000,000Source | 1,204,000,000Source | 1,602,000,000Source | 2,006,000,000Source |
| InterestExpenseOnLeaseLiabilitiesEUR | 45,000,000Source | 42,000,000Source | 39,000,000Source | 40,000,000Source |
| OtherEmployeeExpenseEUR | 736,000,000Source | 766,000,000Source | 531,000,000Source | 267,000,000Source |
| OtherOperatingIncomeExpenseEUR | -4,923,000,000Source | -3,789,000,000Source | -2,979,000,000Source | -1,231,000,000Source |
| PostemploymentBenefitExpenseDefinedBenefitPlansEUR | — | — | — | 236,000,000Source |
| ProfitLossAttributableToNoncontrollingInterestsEUR | 38,000,000Source | 58,000,000Source | 36,000,000Source | 113,000,000Source |
| ProfitLossAttributableToOwnersOfParentEUR | 7,813,000,000Source | 5,560,000,000Source | 5,400,000,000Source | 8,371,000,000Source |
| ProfitLossFromOperatingActivitiesEUR | 6,344,000,000Source | 7,252,000,000Source | 7,875,000,000Source | 10,656,000,000Source |
| ResearchAndDevelopmentExpenseEUR | 7,842,000,000Source | 7,394,000,000Source | 6,728,000,000Source | 6,706,000,000Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodEUR | — | — | -115,000,000Source | 68,000,000Source |
| TaxRateEffectOfForeignTaxRatesnumber | -0.12Source | -0.13Source | -0.14Source | -0.07Source |
Filing attachments
d143371dex991.htm · 6-K · 2026-10-01
Exhibit 99.1 Press Release Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies from Regeneron Regeneron to receive $1 billion upfront, with potential for up to an additional $7 billion in future milestone …
Read attachment ↗d517247dex991.htm · 6-K · 2026-09-17
Exhibit 99.1 Press Release Sanofi and Cheplapharm to create new strategic partnership in mature medicines Paris, September 14, 2026. Sanofi and Cheplapharm, a European leader in well-established medicines, today announced their intention to create a strategic partnership under which Cheplapharm would take over from Sanofi a selection of 20 mature medicines and three manufacturing sites worldwide. In return, Sanofi will receive a 26.4% equity stake in Cheplapharm, building on a collaboration t…
Read attachment ↗d143789dex991.htm · 6-K · 2026-08-06
Exhibit 99.1 Press Release Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has approved an extension of the indication for MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants from six weeks of age to help protect against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. MenQu…
Read attachment ↗d150377dex991.htm · 6-K · 2026-07-27
Exhibit 99.1 Press Release Sanofi evolves its Executive Committee to support its next strategic chapter Paris, July 21, 2026. Sanofi today announced an evolution of its Executive Committee, bringing together a focused leadership team across its businesses, scientific organization and key global functions as the company continues to deliver on its priorities and prepares its next strategic chapter. Effective September 1, 2026, Sanofi’s Executive Committee will comprise: François Roger, E…
Read attachment ↗d150377dex992.htm · 6-K · 2026-07-27
Exhibit 99.2 Press Release Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews Paris, July 24, 2026. Sanofi today announced the discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis (AD). This decision not to submit for global regulatory reviews was made as part of an ongoing strategic assessment of the pipeline. Sanofi has determined that the totality of efficac…
Read attachment ↗d106024dex991.htm · 6-K · 2026-07-17
Exhibit 99.1 Press Release Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena administered via the CirCLIQ® on-body injector (OBI) offers a treatment experience designed with patients and HCPs in mind The first anticancer treatment to be administered through an OBI, and the first MM treatment available by both SC OBI and manual SC administration in the US Efficacy of Sarclisa now available in SC …
Read attachment ↗